ANDOVER, Mass.--(BUSINESS WIRE)--Oct. 11, 2007--Diomed Holdings, Inc. (AMEX: DIO), a leading developer and marketer of minimally invasive medical technologies, including its patented EndoVenous Laser Treatment (EVLT(R)) for varicose veins, today announced at the 2007 American College of Surgeons 93rd Annual Clinical Congress in New Orleans, LA the launch of its next generation EVLT(R) procedure kit, that includes the new Spotlight OPS(TM) Sheath.

The new 4 French Spotlight One-Piece Sheath (OPS(TM)) represents a significant advance in sheath technology that sets a new standard for size, speed and visibility. Designed in collaboration with leading interventional physicians, the Spotlight OPS(TM) Sheath is smaller, faster, and brighter under ultrasound than previous generation sheaths and has all the features to make the already efficient EVLT(R) procedure even more so.

"By eliminating the dilator, Diomed was able to create one of the smallest sheath profiles used in endovenous ablation as well as eliminate a step from the procedure" stated Carl Black, MD, an interventional radiologist, leading EVLT(R) practitioner and an early user of the new Spotlight OPS(TM) Sheath.

Available in 25cm, 55cm, and 80cm lengths, EVLT(R) kits with the Spotlight OPS Sheath will be sold in addition to Diomed's standard offering of 45cm and 70cm EVLT kits.

"We expect Spotlight OPS(TM) to become our flagship procedure kit, as our EVLT(R) kit business becomes the most significant component of our revenue base," stated James A. Wylie, President and Chief Executive Officer of Diomed Holdings, Inc.

Mr. Wylie added, "The Spotlight OPS(TM) product launch joins a number of other Diomed strategic initiatives we have brought to the varicose vein treatment market, including our unique customer designed "MBA" practice development program, CorePack,(TM) TDS Pump(TM), and VeinViewer(TM) --- all focused on providing physicians with state-of the-art tools required to build a thriving vein practice."

About Diomed

Diomed develops and commercializes minimal and micro-invasive medical procedures that use its proprietary laser technologies and disposable products. Diomed's EVLT(R) laser vein ablation procedure is used in varicose vein treatments. Diomed also provides photodynamic therapy (PDT) for use in cancer treatments, and dental and general surgical applications. The EVLT(R) procedure and the Company's related products were cleared by the United States FDA in January of 2002. Along with lasers and single-use procedure kits for its EVLT(R) laser vein treatment, the Company provides its customers with state of the art physician training and practice development support. Additional information is available on the Company's website: www.evlt.com.

EVLT(R) is a registered trademark of Diomed Inc., Andover, MA.

Safe Harbor
Safe Harbor statements under the Private Securities Litigation Reform Act of 1995: Statements in this news release looking forward in time involve risks and uncertainties, including the risks associated with trends in the products markets, reliance on third party distributors in various countries outside the United States, reoccurring orders under OEM contracts, market acceptance risks, technical development risks and other risk factors. These statements relate to our future plans, objectives, expectations and intentions. These statements may be identified by the use of words such as "may," "will," "should," "potential," "expects," "anticipates," "intends," "plans," "believes" and similar expressions. These statements are based on our current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties. Our actual results could differ materially from those discussed in these statements. Our 2006 Annual Report on Form SEC 10-KSB (the "Annual Report") contains a discussion of certain of the risks and uncertainties that affect our business. We refer you to the "Risk Factors" on pages 19 through 34 of the Annual Report for a discussion of certain risks, including those relating to our business as a medical device company without a significant operating record and with operating losses, our risks relating to our commercialization of our current and future products and applications and risks relating to our common stock and its market value. Diomed disclaims any obligation or duty to update or correct any of its forward-looking statements.

CONTACT: Diomed Holdings, Inc.
Christopher J. Geberth, 866-4DIOMED
VP Finance
cgeberth@diomedinc.com
or
Burns McClellan, Investor Relations
Carney Noensie, 212-213-0006
cnoensie@burnsmc.com

SOURCE: Diomed Holdings, Inc.